Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
23.77
-0.31 (-1.29%)
Jul 1, 2026, 9:59 AM EDT - Market open
Capricor Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
231
Market Cap
1.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 22.27M | -2.91M | -11.55% |
| Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
| Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
| Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
| Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
| Dec 31, 2019 | 1.01M | -666.33K | -39.87% |
| Dec 31, 2018 | 1.67M | -994.98K | -37.32% |
| Dec 31, 2017 | 2.67M | -1.33M | -33.32% |
| Dec 31, 2016 | 4.00M | -1.52M | -27.53% |
| Dec 31, 2015 | 5.52M | 730.95K | 15.27% |
| Dec 31, 2014 | 4.79M | 4.28M | 851.19% |
| Dec 31, 2013 | 503.23K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 1.35M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 596.34M |
| Ardelyx | 427.68M |
| Immunocore Holdings | 412.81M |
| MannKind | 360.78M |
| Immatics | 43.00M |
| Inhibrx Biosciences | 1.30M |
CAPR News
- 4 days ago - Capricor announces FDA advisory committee meeting to review Deramiocel BLA - TheFly
- 5 days ago - Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 5 days ago - Capricor presents five-year data from HOPE-2 open-label extension study - TheFly
- 5 days ago - Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference - GlobeNewsWire
- 11 days ago - Caprock Announces Closing of Private Placement - Newsfile Corp
- 13 days ago - Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp. - Newsfile Corp
- 14 days ago - Capricor Therapeutics management to meet with Oppenheimer - TheFly
- 18 days ago - Caprock Announces Proposed Private Placement - Newsfile Corp